Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Vir Biotechnology Inc. VIR, +15.99% were up 12.8% in premarket trading on Wednesday, the day after it was announced that the stock will join the S&P SmallCap 600 SML, -0.20% , effective April 4. The company is led by George Scangos, the former CEO of Biogen Inc. BIIB, -0.06% ; it has one authorized therapy, the COVID-19 monoclonal antibody, sotrovimab.

Vir's stock is up 12% after news it will join the S&P SmallCap 600

Adagio Therapeutics

Markets looked to take a breather after a huge surge in recent weeks.

These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning

Camden Property

Matador Resources

People's United Financial

NEW YORK , March 29, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Camden Property Trust (NYSE: CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constituent Matador Resources Co. (NYSE: MTDR) will replace Camden Property Trust in the S&P MidCap 400 and Vir Biotechnology, Inc. (NASD: VIR) will replace Matador Resources in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 4.  S&P 500 constituent M&T Bank Corp. (NYSE: MTB) is acquiring People's United Financial in a deal expected to be completed on or about April 4.

Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600

GlaxoSmithKline

The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.

FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude.

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

SAN FRANCISCO, March 25, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by Vir, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant. GSK and Vir are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion.

US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant

Clover Health Investments

Penumbra

Looking for small healthcare companies with huge revenue opportunities? Try these.

These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022

Merck

Walgreens

CVS Health

Kroger

Rite Aid

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy and diagnostic industries over the coming year.

Health Care Stocks to Watch as Test to Treat Plan Looks to Prevent Lockdowns

Moderna

Pfizer

Thermo Fisher Scientific

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy, and diagnostic industries over the coming year.

Test to Treat Plan can Boost these Stocks

SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, at 10:30 a.m. ET.

Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference

Illumina

VIR vs. ILMN: Which Stock Is the Better Value Option?

VIR vs. ILMN: Which Stock Should Value Investors Buy Now?

Vir Biotechnology, Inc. (VIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Vir Biotechnology, Inc. (VIR)

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Q4 Earnings and Revenues Beat Estimates

– Significant progress made increasing global patient access to sotrovimab;  approximately 1.7 million doses sold to date –

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Aerie Pharmaceuticals

Emergent BioSolutions

Editas Medicine

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vir Biotechnology, Inc. (VIR) Reports Next Week: Wall Street Expects Earnings Growth

Vir's prospects depend entirely on the SARS-COV2 virus and emerging variants, if any.

Vir Biotechnology: Some Option Strategies For July

Vir Biotechnology and GlaxoSmithKline expect to develop 2 million doses of Covid-19 antiviral Sotrovimab in the 1st half of 2022, with more to follow in the 2nd half of 2022.

Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet

Ensign Group

Envista Holdings Corp

Are these on your list of best health care stocks to buy right now?

Hot Stocks To Buy Right Now? 3 Health Care Stocks For Your Watchlist

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

Intercept Pharma

Viking Therapeutics

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

3 Biotech Stocks That Are too Cheap to Ignore

Eli Lilly

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's LLY COVID-19 treatments. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.

Vir (VIR) Announces Encouraging Data on COVID-19 Antibody

Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will still be effective against the BA.2 omicron variant, Vir's chief executive said.

News for Vir Biotechnology Stock (VIR)